Lilly First-Quarter Tumbles on Zyprexa Generic Competition

Lilly First-Quarter Tumbles on Zyprexa Generic Competition

JB Reed/Bloomberg News

Revenue dropped 4 percent to $5.6 billion, hurt by declining sales for Zyprexa after copies of the drug were allowed on the market in the fourth quarter.